Firmagon is a medicine used to treat cancer of the prostate (a gland of the male reproductive system) in adult men when the cancer is ‘hormone-dependent’, which means that it responds to treatments that reduce the levels of the hormone testosterone. It is used: • to treat advanced hormone-dependent prostate cancer. ‘Advanced’ means that the cancer has spread beyond the pelvis to nearby tissues such as lymph nodes and bone; • before or together with radiotherapy to treat high-risk localised or locally advanced hormone-dependent prostate cancer. ‘High-risk localised’ means that the cancer is likely to spread beyond the prostate gland to nearby tissues and become ‘locally advanced’. Firmagon contains the active substance degarelix.
Therapeutic Indication
### Therapeutic indication FIRMAGON is a gonadotrophin releasing hormone (GnRH) antagonist indicated: \- for treatment of adult male patients with advanced hormone-dependent prostate cancer. \- for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. \- as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
Therapeutic Area (MeSH)
ATC Code
L02BX02
ATC Item
degarelix
Pharmacotherapeutic Group
Endocrine therapy
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| degarelix | N/A | 地加瑞克 |
EMA Name
Firmagon
Medicine Name
Firmagon
Aliases
N/ANo risk management plan link.
